Bristol Myers Squibb has announced the presentation of new data from its targeted protein degradation platform at the 2025 European Hematology Association (EHA) Annual Congress, scheduled from June 12-15 in Milan, Italy. The presentations will feature updated clinical findings on the company's investigational oral CELMoD™ agents, including mezigdomide and iberdomide for multiple myeloma, and golcadomide for non-Hodgkin lymphoma. Additionally, the first results evaluating the company's first-in-class, oral BCL6 ligand-directed degrader (BMS-986458) in non-Hodgkin lymphoma will be presented. These developments highlight Bristol Myers Squibb's ongoing commitment to advancing targeted protein degradation therapies in cancer treatment.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。